Institute of Hereditary Metabolic Diseases
Director // Prof. Dr. med. univ. Florian Lagler
Lysosomal storage diseases clinically manifest as chronic progressive impairment of multiple organ systems such as the skeleton, central nervous system, and heart. These diseases often come with severe physical limitations and a reduced life expectancy.
Currently, there is a significant medical need in the area of all lysosomal storage diseases. Recent research has yielded promising results for individualized therapeutic approaches. Moreover, we have developed innovative methods to facilitate diagnostics. These advances open new perspectives for optimized treatments and early diagnosis, strengthening the hope for improved quality of life for those affected.
Research Goals and Projects
Our research aims to improve treatability and patient safety in the area of inborn metabolic diseases. Our topics include:
- Patient-centered, personalized therapy strategies
- Repurposing approved immunomodulators (off-label)
- Systemic inflammations, neuroinflammation, and degeneration
- Perception of innovative and approved therapy options
- Evidence-based decision models for benefit-risk assessment
- Tools for accurate early diagnosis
- Optimizations in anesthesia
- (Pro-)inflammatory biomarkers for monitoring progression
Impressions from the Institute
Contact
Prof. Florian Lagler, head of the institute, will be happy to provide information on all topics in the field of inborn metabolic diseases:
